ArticleFree radical biology & medicine2014
Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury.
Article in Free radical biology & medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Boronate-Based Bioactive Compounds Activated by Peroxynitrite and Hydrogen Peroxide.Redox biochemistry and chemistry · 2024Article
- Targeting Ferroptosis: A Novel Strategy for the Treatment of Atherosclerosis.Mini reviews in medicinal chemistry · 2024Review
- Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine.Scientific reports · 2022Article
- From Iron Metabolism to Ferroptosis: Pathologic Changes in Coronary Heart Disease.Oxidative medicine and cellular longevity · 2022Review
- Programmed Cell Death: Complex Regulatory Networks in Cardiovascular Disease.Frontiers in cell and developmental biology · 2021Review
- Activity-Based Sensing: A Synthetic Methods Approach for Selective Molecular Imaging and Beyond.Angewandte Chemie (International ed. in English) · 2020Review
- Atrial fibrillation in β-thalassemia patients with a focus on the role of iron-overload and oxidative stress: A review.Journal of cellular physiology · 2019Review
- Stem Cell-Derived Exosomes Prevent Aging-Induced Cardiac Dysfunction through a Novel Exosome/lncRNA MALAT1/NF-Oxidative medicine and cellular longevity · 2019Article
- Modifying aroylhydrazone prochelators for hydrolytic stability and improved cytoprotection against oxidative stress.Bioorganic & medicinal chemistry · 2018Article
- The hydrolytic susceptibility of prochelator BSIH in aqueous solutions.Bioorganic & medicinal chemistry letters · 2017Article
- Crystal structure of (Acta crystallographica. Section E, Crystallographic communications · 2017Article
- Females Are Protected From Iron-Overload Cardiomyopathy Independent of Iron Metabolism: Key Role of Oxidative Stress.Journal of the American Heart Association · 2017Article
- Stimulus-Responsive Prochelators for Manipulating Cellular Metals.Accounts of chemical research · 2016Article
- Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injury.Toxicology · 2016Article
- Crystal structures of (E)-N'-(2-hy-droxy-5-methyl-benzyl-idene)isonicotinohydrazide and (E)-N'-(5-fluoro-2-hy-droxy-benzyl-idene)isonicotinohydrazide.Acta crystallographica. Section E, Crystallographic communications · 2016Article
- The role of glycine in regulated cell death.Cellular and molecular life sciences : CMLS · 2016Review
- Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products.Toxicology · 2016Article
- LC-UV/MS methods for the analysis of prochelator-boronyl salicylaldehyde isonicotinoyl hydrazone (BSIH) and its active chelator salicylaldehyde isonicotinoyl hydrazone (SIH).Journal of pharmaceutical and biomedical analysis · 2015Article
- Iron-induced damage in cardiomyopathy: oxidative-dependent and independent mechanisms.Oxidative medicine and cellular longevity · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
Oxidative stress is a common denominator of numerous cardiovascular disorders. Free cellular iron catalyzes the formation of highly toxic hydroxyl radicals, and iron chelation may thus be an effective therapeutic approach. However, using classical iron chelators in diseases without iron overload poses risks that necessitate more advanced approaches, such as prochelators that are activated to chelate iron only under disease-specific oxidative stress conditions. In this study, three cell-membrane-permeable iron chelators (clinically used deferasirox and experimental SIH and HAPI) and five boronate-masked prochelator analogs were evaluated for their ability to protect cardiac cells against oxidative injury induced by hydrogen peroxide. Whereas the deferasirox-derived agents TIP and TRA-IMM displayed negligible protection and even considerable toxicity, the aroylhydrazone prochelators BHAPI and BSIH-PD provided significant cytoprotection and displayed lower toxicity after prolonged cellular exposure compared to their parent chelators HAPI and SIH, respectively. Overall, the most favorable properties in terms of protective efficiency and low inherent cytotoxicity were observed with the aroylhydrazone prochelator BSIH. BSIH efficiently protected both H9c2 rat cardiomyoblast-derived cells and isolated primary rat cardiomyocytes against hydrogen peroxide-induced mitochondrial and lysosomal dysregulation and cell death. At the same time, BSIH was nontoxic at concentrations up to its solubility limit (600 μM) and in 72-h incubation. Hence, BSIH merits further investigation for prevention and/or treatment of cardiovascular disorders associated with a known (or presumed) component of oxidative stress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.